Literature DB >> 19014899

Weight loss in narcolepsy patients treated with sodium oxybate.

Aatif M Husain1, Ruzica K Ristanovic, Richard K Bogan.   

Abstract

INTRODUCTION: Narcolepsy is often associated with increased body weight. Sodium oxybate has efficacy in many narcolepsy symptoms. The purpose of this study was to evaluate the effects of sodium oxybate on weight in patients with narcolepsy.
METHODS: Charts from three centers of all patients with narcolepsy who had been using sodium oxybate for at least 3 months were reviewed. Patients in whom anti-cataplexy medications were added or withdrawn or wake-promoting medications added after the start of sodium oxybate were excluded from further analysis. In the remainder, pre-sodium oxybate and, most recently, on-sodium oxybate weights were compared using Student's t-tests. Sodium oxybate dose and duration of therapy were also noted.
RESULTS: A total of 54 patients meeting inclusion criteria were identified. Of these 54, 33 (61%) were women; the mean age was 48.3 years. The mean dose of sodium oxybate was 6.9g/night and the duration of therapy was 25 months. The mean pre-sodium oxybate weight was 78.3 (+/-15.7)kg. The most recent on-sodium oxybate weight was 74.9 (+/-15.1, p=0.003). The average weight loss was 3.4kg, whereas the maximum was 30.9kg.
CONCLUSIONS: This study suggests that treatment of patients with narcolepsy with sodium oxybate can result in weight loss.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19014899     DOI: 10.1016/j.sleep.2008.05.012

Source DB:  PubMed          Journal:  Sleep Med        ISSN: 1389-9457            Impact factor:   3.492


  13 in total

Review 1.  Cataplexy and Its Mimics: Clinical Recognition and Management.

Authors:  Sigrid Pillen; Fabio Pizza; Karlien Dhondt; Thomas E Scammell; Sebastiaan Overeem
Journal:  Curr Treat Options Neurol       Date:  2017-06       Impact factor: 3.598

2.  Update on therapy for narcolepsy.

Authors:  Michael J Thorpy
Journal:  Curr Treat Options Neurol       Date:  2015-05       Impact factor: 3.598

3.  Residual social, memory and oxytocin-related changes in rats following repeated exposure to γ-hydroxybutyrate (GHB), 3,4-methylenedioxymethamphetamine (MDMA) or their combination.

Authors:  Petra S van Nieuwenhuijzen; Leonora E Long; Glenn E Hunt; Jonathon C Arnold; Iain S McGregor
Journal:  Psychopharmacology (Berl)       Date:  2010-08-21       Impact factor: 4.530

Review 4.  Treatment Options for Narcolepsy.

Authors:  Lucie Barateau; Régis Lopez; Yves Dauvilliers
Journal:  CNS Drugs       Date:  2016-05       Impact factor: 5.749

5.  Central and peripheral metabolic changes induced by gamma-hydroxybutyrate.

Authors:  Gianina Luca; Julie Vienne; Angélique Vaucher; Sonia Jimenez; Mehdi Tafti
Journal:  Sleep       Date:  2015-02-01       Impact factor: 5.849

Review 6.  Management of Narcolepsy.

Authors:  Lucie Barateau; Régis Lopez; Yves Dauvilliers
Journal:  Curr Treat Options Neurol       Date:  2016-10       Impact factor: 3.598

7.  Glucose and fat metabolism in narcolepsy and the effect of sodium oxybate: a hyperinsulinemic-euglycemic clamp study.

Authors:  Claire E H M Donjacour; N Ahmad Aziz; Sebastiaan Overeem; Andries Kalsbeek; Hanno Pijl; Gert Jan Lammers
Journal:  Sleep       Date:  2014-04-01       Impact factor: 5.849

8.  Plasma total ghrelin and leptin levels in human narcolepsy and matched healthy controls: basal concentrations and response to sodium oxybate.

Authors:  Claire E H M Donjacour; Daniel Pardi; N Ahmad Aziz; Marijke Frölich; Ferdinand Roelfsema; Sebastiaan Overeem; Hanno Pijl; Gert Jan Lammers
Journal:  J Clin Sleep Med       Date:  2013-08-15       Impact factor: 4.062

Review 9.  A practical guide to the therapy of narcolepsy and hypersomnia syndromes.

Authors:  Emmanuel J M Mignot
Journal:  Neurotherapeutics       Date:  2012-10       Impact factor: 7.620

10.  Long-term tolerability and maintenance of therapeutic response to sodium oxybate in an open-label extension study in patients with fibromyalgia.

Authors:  Michael Spaeth; Cayetano Alegre; Serge Perrot; Youyu Wang; Diane R Guinta; Sarah Alvarez-Horine; Irwin Russell
Journal:  Arthritis Res Ther       Date:  2013-11-11       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.